Noramco Group Establishes Sterile Injectable Manufacturing Capabilities with $25 Million Investment

The Noramco Group, a Wilmington, Del.-based provider of products and services to the API and drug product supply chains, has announced a $25 million investment in the Whippany, NJ, facility of one of its subsidiaries, Halo Pharma (1). The purpose of the investment, The Noramco Group announced on March 10, 2025, is to establish sterile injectable manufacturing capabilities—namely ready-to-use syringe, cartridge, and vial filling—to address capacity shortages in the injectable supply chain in the United States that the company said are “critical.”

“This investment is a significant step in our commitment to build on our position as one of the only fully integrated domestic supply options for our customers,” said Lee Karras, CEO of The Noramco Group, in the company’s press release (1). “We recognize the challenges facing the industry and are dedicated to providing solutions that address both immediate and long-term supply chain needs. We anticipate the new line to be qualified and operational within the next 12 months, ensuring we can support customers with the high-quality capacity they require. While this investment enhances our capabilities with contemporary technologies, with the addition of sterile manufacturing we remain committed to our already established and proven focus on manufacturing APIs, oral solid dose, and liquid dosage forms, which continue to be essential in meeting our customers’ needs.”

Halo Pharma, a contract development and manufacturing organization, has focused on oral solid dose, semi-solid, and liquid formulation manufacturing for the past 20 years, but the Whippany facility will now undergo “significant renovations,” The Noramco Group said in the release, to maintain those primary production capabilities while adding a new sterile filling line (1). That installation will be done over the balance of 2025, upgrading the facility to meet European Union Annex 1 compliance for European market access, as well as maintaining US quality standards.

In its March 2025 issue, Pharmaceutical Technology® examined the state of supply chains across the bio/pharmaceutical industry and how contract manufacturers are responding, including a listing of company news in the same vein as The Noramco Group’s March 10 release (2).

The announcement of the $25 million investment was made just days prior to the one-year anniversary of the launch of The Noramco Group, which Noramco announced on March 14, 2024 as the umbrella term for its namesake API manufacturing business plus fellow subsidiaries Purisys, located in Athens, Ga., and Halo Pharma, which has operations not only in New Jersey but also Montreal (3). At that time, Noramco had only recently (in November 2023) acquired Halo Pharmaceuticals, which was actually the former name of Cambrex Drug Product Business Unit as of when the transaction was made (4).

The March 2025 news also comes one week before the start of the 2025 Drug, Chemical & Associated Technologies Association (DCAT) Week, to be held from March 17–20 in New York City (5). The Noramco Group said its executives will be on site to provide more information about the new sterile injectable manufacturing capabilities at the Halo Pharma site, and DCAT Member Companies are invited to interface with them during the event at the Intercontinental New York Barclay Hotel, suites 1007, 1141, and 1223.

Pharmaceutical Technology® Group will be covering DCAT Week 2025 in depth, prior to, during, and after the event, and the landing page for all relevant content can be accessed here.

References

1. The Noramco Group. The Noramco Group Invests $25 Million in Halo Pharma’s Whippany Facility to Offer Sterile Injectable Manufacturing. Press Release. March 10, 2025.
2. Lavery, P. Adopting Flexible Strategies to Combat Capacity Shortages. Pharmaceutical Technology 2025, 49 (2).
2. Noramco. Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider. Press Release. March 14, 2024.
3. Noramco. Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit. Press Release. Nov. 2, 2023.
4. The Noramco Group. Noramco Group Announces $25 Million Sterile Injectable Manufacturing Investment at DCAT Week 2025. Noramco.com (accessed March 10, 2025).